CompletedNot Applicable

Effect of Continuing vs. Discontinuing ACE Inhibitors on Renal Function After Coronary Angiography

Egypt44 participantsStarted 2024-02-01

Plain-language summary

This clinical trial evaluates whether continuing or withholding ACE inhibitors (specifically Ramipril) before coronary angiography affects the risk of contrast-induced nephropathy (CIN). CIN is a known complication of iodinated contrast exposure, particularly in patients with chronic conditions such as hypertension or diabetes. The trial involves 44 adult patients randomized into two groups: one continuing Ramipril and the other withholding it 48 hours before and restarting 72 hours after the procedure. Renal biomarkers including serum creatinine, NGAL, and superoxide dismutase will be assessed to evaluate renal function.

Who can participate

Age range18 Years – 85 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Adults (≥18 years) scheduled for elective coronary angiography * Currently on ACE inhibitor (Ramipril) * Serum creatinine ≤1.5 mg/dL Exclusion Criteria: * STEMI within last 2 weeks * NYHA Class IV heart failure * CrCl \<50 mL/min * Serum potassium \>5.0 mEq/L * Recent contrast exposure * Pregnancy or breastfeeding * Cardiogenic shock or sepsis * Severe uncontrolled hypertension

What they're measuring

Change From Baseline in Serum Creatinine at 72 Hours Post-Angiography

Timeframe: Baseline and 72 hours post-angiography

Trial details

NCT IDNCT07184918

SponsorTanta University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-06-01

View on ClinicalTrials.gov More Contrast-Induced Nephropathy trials